IMMUNOGEN (IMGN): WHAT TO DO NOW
ImmunoGen (IMGN ) stock has moved up sharply on the news that T-DM1 produced by ImmunoGen improved survival in patients suffering from HER2-Positive Metastatic Breast Cancer. T-DM1 contains DM1 cancer cell killing agent produced by ImmunoGen attached to an HER-2 targeting antibody. This development is mostly already in the stock
September 26, 2011